Atossa Genetics Inc (ATOS) - Total Liabilities
Based on the latest financial reports, Atossa Genetics Inc (ATOS) has total liabilities worth $8.22 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Atossa Genetics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Atossa Genetics Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how Atossa Genetics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Atossa Genetics Inc's balance sheet.
Atossa Genetics Inc Competitors by Total Liabilities
The table below lists competitors of Atossa Genetics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hilbert Group AB Series B
ST:HILB-B
|
Sweden | Skr232.20 Million |
|
Next Entertainment World Co. Ltd
KQ:160550
|
Korea | ₩116.80 Billion |
|
Matricelf Ltd
TA:MTLF
|
Israel | ILA2.70K |
|
INVENIA Co. Ltd
KQ:079950
|
Korea | ₩32.15 Billion |
|
MindForge Inc.
NASDAQ:MF
|
USA | $1.37 Million |
|
CyberOne Co. Ltd.
KQ:356890
|
Korea | ₩6.92 Billion |
|
Alarko Gayrimenkul Yatirim Ortakligi AS
IS:ALGYO
|
Turkey | TL6.36 Billion |
|
Green Resources Public Company Limited
BK:GREEN
|
Thailand | ฿195.49 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Atossa Genetics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Atossa Genetics Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Atossa Genetics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Atossa Genetics Inc (2009–2024)
The table below shows the annual total liabilities of Atossa Genetics Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.97 Million | -5.14% |
| 2023-12-31 | $5.24 Million | -5.96% |
| 2022-12-31 | $5.57 Million | +78.12% |
| 2021-12-31 | $3.13 Million | -80.06% |
| 2020-12-31 | $15.68 Million | +1065.77% |
| 2019-12-31 | $1.34 Million | -53.88% |
| 2018-12-31 | $2.92 Million | +137.92% |
| 2017-12-31 | $1.23 Million | +17.01% |
| 2016-12-31 | $1.05 Million | -58.14% |
| 2015-12-31 | $2.50 Million | +10.40% |
| 2014-12-31 | $2.27 Million | +61.00% |
| 2013-12-31 | $1.41 Million | -14.73% |
| 2012-12-31 | $1.65 Million | +9.15% |
| 2011-12-31 | $1.51 Million | +74.44% |
| 2010-12-31 | $866.86K | +1511.84% |
| 2009-12-31 | $53.78K | -- |
About Atossa Genetics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more